TCMCB 07
Alternative Names: B07; TCMCB-07Latest Information Update: 25 Apr 2024
At a glance
- Originator Endevica Bio
- Class Cyclic peptides; Melanocortins
- Mechanism of Action Melanocortin type 3 receptor modulators; Melanocortin type 4 receptor antagonists
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Phase I Cachexia
Most Recent Events
- 23 Apr 2024 Endevica Bio plans a phase II trial for cachexia in 2024
- 02 Jun 2023 Pharmacokinetics and adverse events data from phase-I trial in Cachexia (In volunteers) presented at the 59th Annual Meeting of the American Society of Clinical Oncology (ASCO-2023)
- 01 Feb 2023 Endevica Bio and Orbit Discovery agree to co-develop cachexia therapeutics